Clinical trials
Hepatocellular Carcinoma Resectable clinical trials
Below are recruiting hepatocellular carcinoma resectable clinical trials, each written for real people, not researchers. We’re tracking 206 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT05433467Recruiting
CT-guided locating for tiny liver cancer before surgery
This study tests a CT-guided method to find and precisely locate very small liver cancer spots before surgery. It may help surgeons remove the tumor more accurately when standard scans cannot clearly see it.
Yangzhou, JiangsuAges 18 years+ - NCT05516628RecruitingPhase 2
Adjuvant atezolizumab plus bevacizumab after liver cancer surgery
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
SingaporeAges 21–90 - NCT05528952RecruitingPhase 2
Vaccine plus immunotherapy for unresectable liver cancer
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
BesançonAges 18 years+ - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT05791448RecruitingPhase 1
AU409 for advanced liver cancers or liver-spread tumors
This Phase 1 trial studies AU409, a new medicine, for advanced primary liver cancers or other solid tumors mainly in the liver. It aims to find a safe dose and see how well the treatment works for people whose usual options have not worked or are not available.
Los Angeles, CaliforniaAges 18 years+ - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05992220RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
SeoulAges 20–79 - NCT06034977RecruitingPhase 2
ADI-PEG 20 and Lenvatinib for liver cancer
This trial tests a combination of two drugs, ADI-PEG 20 and Lenvatinib, for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination can help shrink or control the cancer.
TaoyuanAges 18 years+ - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06339424RecruitingPhase 2
Atezolizumab and Bevacizumab with radiation for liver cancer that can't be removed
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06375486RecruitingPhase 2
Ivonescimab and HAIC for Unresectable Liver Cancer
This trial tests a combination of a targeted immunotherapy drug (ivonescimab) and a liver-directed chemotherapy infusion (HAIC) for people with liver cancer that cannot be removed by surgery. It may be an option if you have not had prior systemic treatment for your liver cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06382103Recruiting
Liver cancer study after surgery or pre-surgery therapy
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
ShanghaiAges Any age - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06571396Recruiting
Surgery risks after immunotherapy for liver cancer
This study looks at the risks of surgery in people with liver cancer who received immunotherapy before or instead of surgery. It aims to understand how safe and effective this approach is.
Jinan, ShandongAges 18 years+ - NCT06581315Recruiting
Donafenib after surgery for high-risk liver cancer
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06623474Recruiting
Fat markers in blood for liver cancer study
This study is for people having liver cancer surgery. It will look at certain fats in your blood to see if they can help doctors understand and track liver cancer better.
Guangzhou, GuangdongAges 18–80 - NCT06652243RecruitingEarly Phase 1
Cell therapy for advanced liver cancer with GPC3 protein
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT06762782RecruitingPhase 2
Lenvatinib after liver cancer surgery to prevent recurrence
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
Nanjing, JiangsuAges 18–80 - NCT06873269Recruiting
Holmium-166 radiation therapy for liver cancer
This trial tests a radiation treatment for liver cancer that cannot be removed with surgery or ablation. Tiny beads containing Holmium-166 are injected into the liver's blood supply to target the tumor directly.
BrusselsAges 18 years+
Hear when a new Hepatocellular Carcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma resectable?
- Yes. Clin2 currently lists 206 recruiting hepatocellular carcinoma resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.